This is the first of a series of blogs covering the 58th ASH Annual Meeting and Exposition in San Diego (#ASH16) conference over the next few days. Check back for more news from the meeting.
Harnessing a patient’s immune system to fight cancer is a hot topic. So hot, in fact, that today’s Leukemia & Lymphoma Society (LLS) satellite symposium on the topic preceding the 58th ASH Annual Meeting and Exposition in San Diego (#ASH16) was at capacity with more than 600 attendees.
The LLS-hosted event, “Immunotherapy: Transformation of Therapies for Blood Cancers,” was among several symposia taking place in advance of the annual meeting. More than 20,000 hematologists, patient advocacy groups and representatives from the biopharmaceutical industry will come together over the next few days to share their latest clinical trial data in blood cancers and other disorders of the blood.
The eager audience was here today with good reason – the symposium panelists included some of the most world-renowned experts in the rapidly advancing field of immunotherapy. Researchers are investigating an array of approaches to employ the body’s immune system to kill cancer cells.
